A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

doi:10.3748/wjg.v13.i5.732

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2061)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

260

HTML

1489

Figures (1-7)

149

Tables (1-3)

163

Sum=2061

Feb 7, 2007 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Feb 7, 2007; 13(5): 732-739
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.732

Full Size Figure Download Figure

Figure 2 Change from baseline in the number of CSBMs per week (wk 1-4) by treatment (ITT population). Footnote: ^bP = 0.0002 vs placebo; Mean number of CSBMs per week at baseline: tegaserod 0.36; placebo 0.31.

Citation: Lin SR, Ke MY, Luo JY, Yuan YZ, Wang JY, diTommaso S, Walter V, Huang J. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation. World J Gastroenterol 2007; 13(5): 732-739
URL: https://www.wjgnet.com/1007-9327/full/v13/i5/732.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i5.732